Mean COMPASS-31 questionnaire scores by autoantibody for the 83 systemic sclerosis (SSc) patients with complete Euroimmun autoantibody profiles.
| Autoantibody Subtype | n/N (%) | Mean Compass Score (SD) | p | Adjusted Model 1: Age, Sex, Race | Adjusted Model 2: Model 1 + Disease Duration |
|---|---|---|---|---|---|
| Anti-centromere | |||||
| Positive | 21/83 (25) | 30.7 (17.9) | 0.04 | β 4.3 (0.3–8.3), p = 0.04 | β 2.6 (−1.5 to 6.6), p = 0.21 |
| Negative | 62/83 (75) | 21.3 (13.8) | |||
| Anti-topoisomerase I | |||||
| Positive | 31/83 (37) | 21.2 (13.6) | 0.24 | β −2.5 (−6.2 to 1.2), p = 0.19 | β −1.7 (−5.3 to 1.8), p = 0.34 |
| Negative | 52/83 (63) | 25.1 (16.3) | |||
| Anti-RNA polymerase III | |||||
| Positive | 19/83 (23) | 17.9 (12.4) | 0.04 | β −3.5 (−7.7 to 0.7), p = 0.10 | β −2.3 (−6.4 to 1.7), p = 0.26 |
| Negative | 64/83 (77) | 25.4 (15.8) |
Student t test was used to compare COMPASS-31 scores between patients with and without each autoantibody. Multivariable linear regression analysis was used to adjust for age, sex, and race (Model 1) and age, sex, race, and disease duration (Model 2). Data are presented as the β coefficient and the 95% CI.